ADAM17 and neoplasm: Release of sIL-6R by ADAM17 to promote IL-6 trans-signaling can be facilitated by tumor cells and macrophages [52,53], whereas ADAM17 on myeloid cells is speculated to release EGF-R ligands and activate EGF-R signaling in an autocrine manner, as well as on macrophages.